Not the Usual Suspects: FDA Seeks New Advisors for Risk Communication Committee
This article was originally published in RPM Report
Executive Summary
The Food & Drug Administration is bringing a whole new constituency into the advisory committee process with the creation of an expert panel focused on improving the way the agency communicates risk information to the public. For industry, success will require even greater attention to foresee and address safety issues.